Extending the Reach

Synosia Therapeutics is developing six clinical-stage assets acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach into new therapeutic areas.

For doctors, this can mean new treatment options for anxiety, Parkinson’s, drug dependency and other key disorders. For patients, it can mean improved quality of life. For Synosia’s partners, it can mean a return on the millions of dollars invested in the development of the Synosia pipeline.